Nom du produit:2-Chloro-4-[3-iodo-1-(1-methylethyl)-1H-pyrazol-4-yl]pyrimidine

IUPAC Name:2-chloro-4-[3-iodo-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidine

CAS:1269440-58-5
Formule moléculaire:C10H10ClIN4
Pureté:95%+
Numéro de catalogue:CM330056
Poids moléculaire:348.57

Unité d'emballage Stock disponible Prix($) Quantité
CM330056-100mg 1-2 Weeks ǜǜțȁ
CM330056-250mg 3-4 Weeks ǜƀƦț
CM330056-1g 3-4 Weeks ưƦNJƦ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1269440-58-5
Formule moléculaire:C10H10ClIN4
Point de fusion:-
Code SMILES:CC(N1N=C(I)C(C2=NC(Cl)=NC=C2)=C1)C
Densité:
Numéro de catalogue:CM330056
Poids moléculaire:348.57
Point d'ébullition:
N° Mdl:
Stockage:2-8°C, sealed storage, away from moisture and light

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.
Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Encorafenib plus Binimetinib
U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.